Article - Pharmacist Digest

Coalition wages campaign for retractions of Richard Lynn’s racist journal articles

STAT

JUNE 20, 2024

A coalition of researchers, historians, and journalists is urging that major scientific publishers, including Elsevier and Springer, retract the racist articles of an academic known — and sometimes lauded for — a long career espousing ideas of racial superiority and eugenics.

Opinion: Journals that published Richard Lynn’s racist ‘research’ articles should retract them

STAT

JUNE 20, 2024

In 2012, the Elsevier journal Personality and Individual Differences published a special issue that included articles with titles like “Life history theory and race differences: An appreciation of Richard Lynn’s contribution to science” and “National IQs and economic outcomes.”

It’s time to stop treating menopause like a disease, researchers argue in series of Lancet articles

STAT

MARCH 5, 2024

The article calls for a reframing of menopause and a management approach that is not simply focused on medical interventions that relieve symptoms. One in eight people is postmenopausal, and about 50 million women enter menopause every year.

Questions about Pfizer’s GenAI ‘Health Answers’

STAT

MARCH 4, 2025

It feels a little bit like typing queries into Google and getting answers from WebMD or another SEO-optimized health resource, without having to actually read (or skim) a whole article. Read the rest…

10 of our most popular articles in 2022

PharmaVoice

NOVEMBER 30, 2022

Methadone, rock ‘n’ roll, clinical trial overhauls — here’s a look at our most-read stories of the year.

STAT+: U.K. lawmaker wants regulators to probe pharma companies over ‘misleading’ Covid-19 vaccines statements

STAT

FEBRUARY 14, 2025

In the latest instance, the Prescription Medicines Code of Practice Authority, a self-regulating arm of the Association of the British Pharmaceutical Industry, pointed to two online articles and four tweets that were made in connection with recruiting patients.

Vaccines

Vaccines Communication Pharmaceutical Companies Pharmaceutical Companies

Journals issue corrections noting vaping researchers’ undisclosed ties to Juul

STAT

JUNE 25, 2024

WASHINGTON — A journal published by the American Medical Association has corrected four articles from two of the nation’s top tobacco researchers, Ray Niaura and David Abrams, after STAT uncovered undisclosed ties the New York University professors had with the e-cigarette company Juul. Read the rest…

Pharmaceutical Marketing Articles: Insights, Trends, and Strategies for Pharma Teams

Pharma Marketing Network

FEBRUARY 17, 2025

For pharma marketing teams, reading pharmaceutical marketing articles is like having a roadmap to success. These articles highlight industry trends, share real-world case studies, and provide actionable strategies to sharpen your marketing campaigns. For marketing teams, these articles are a source of inspiration and knowledge.

Vaccines

10 of our most read articles in 2023

PharmaVoice

DECEMBER 22, 2023

A presidential candidate, a changing biotech market and an enduring murder mystery — here are PharmaVoice’s most-read articles this year.

Article retractions muddy MDMA waters after FDA denial

pharmaphorum

AUGUST 12, 2024

Journal retracts three articles on MDMA-assisted psychotherapy, shortly after FDA blocks approval of @Lykos_PBC's therapy for PTSD

STAT+: The U.S. has relied on cheap, effective generic drugs for 40 years. Now that promise is under threat

STAT

SEPTEMBER 24, 2024

STAT is co-publishing this article by Tradeoffs. Lisa Ann Trainor struggled to stay on top of schoolwork, hold a job or even perform basic tasks like laundry for six exhausting years. Then, in 2018, she finally found a drug that kept her ADHD in check. Continue to STAT+ to read the full story…

Drug Pricing

Drug Pricing Drug Development

STAT+: NEJM aims to hold AI to account with new publication

STAT

DECEMBER 11, 2023

The journal will also publish review articles, policy perspectives, and educational materials for physicians and computer scientists. Many recent articles published in top-tier journals have envisioned a future state where AI transforms vast swaths of medical practice.

10 of our most read articles of 2024

PharmaVoice

DECEMBER 20, 2024

The high drama of an election year, industry layoffs, patent cliff strategies and other key trends that shaped pharma in 2024.

Heart disease experts in their own words: ‘This is solvable and this is preventable’

STAT

OCTOBER 15, 2024

Nearly all of them, as a related article details, pointed to a crisis in primary care. Over the last few months, STAT put that question to nearly a dozen experts in cardiology, primary care, endocrinology, and vascular disease. Read the rest…

Opinion: Readers respond to essays on long Covid, hypochondria, and more

STAT

JUNE 22, 2024

First Opinion is STAT’s platform for interesting, illuminating, and maybe even provocative articles about the life sciences writ large, written by biotech insiders, health care workers, researchers, and others.

How skeptical should you be of an after-the-fact subgroup analysis in a failed clinical trial?

STAT

OCTOBER 31, 2023

This article was adapted from STAT’s latest report , “Subgroup analysis: how to evaluate post hoc tests for significance in failed clinical trials.” ” C linical trials of newly developed drugs often don’t work out. Read the rest…

Mistakes happen in research papers. But corrections often don’t

STAT

JANUARY 10, 2023

Cell, EMBO, and Science have each opened their own investigations into the articles, and both Science and Cell have published “editorial expressions of concern” for the papers, which warn readers that the information in the articles may be questionable, but stop short of making corrections or retractions.

A STAT analysis shows how top drug companies are starting to take action on climate

STAT

SEPTEMBER 28, 2023

This article is adapted from STAT’s exclusive analysis in the STAT Report: “Climate rankings: How top drug companies measure up in combating climate change.” ” D rug companies are major contributors to climate change, both through direct greenhouse gas emissions and especially through their supply chains.

Opinion: First Opinion readers on clinical trials in Africa, compounded semaglutide, depressed mice, and more

STAT

SEPTEMBER 21, 2024

First Opinion is STAT’s platform for interesting, illuminating, and provocative articles about the life sciences writ large, written by biotech insiders, health care workers, researchers, and others.

Compounding

Opinion: What readers have to say about long Covid, FDA and diversity, and more

STAT

JUNE 29, 2024

First Opinion is STAT’s platform for interesting, illuminating, and maybe even provocative articles about the life sciences writ large, written by biotech insiders, health care workers, researchers, and others.

Managing Drug Patent Portfolios Effectively

Drug Patent Watch

NOVEMBER 11, 2024

This article explores key best practices and strategies for optimizing drug patent… Source Effective management of drug patent portfolios is crucial for pharmaceutical companies to maintain market exclusivity, protect revenue streams, and drive innovation.

Pharmaceutical Companies

Pharmaceutical Companies Pharmaceutical Companies

For Eli Lilly’s head scientist, Alzheimer’s results cap a 25-year scientific quest

STAT

MAY 3, 2023

“I’ve been pursuing the same enemy for 25 years,” Skovronsky, now head of research at Eli Lilly, said at the STAT Breakthrough Summit in San Francisco on Wednesday.

Opinion: First Opinion readers respond to psychiatry and social contracts, Medicare and weight loss meds, and more

STAT

JULY 6, 2024

First Opinion is STAT’s platform for interesting, illuminating, and maybe even provocative articles about the life sciences writ large, written by biotech insiders, health care workers, researchers, and others.

Suicide hotlines promise anonymity. Dozens of their websites send sensitive data to Facebook

STAT

JUNE 13, 2023

This article was co-published with The Markup , a nonprofit newsroom that investigates how powerful institutions are using technology to change our society. Sign up for its newsletters here.

STAT+: NYU professors who defended vaping didn’t disclose ties to Juul, documents show

STAT

MAY 6, 2024

Abrams asked Juul officials for talking points, allowed company executives to review an academic article prior to publishing, and attended Juul scientific advisory board meetings, all without disclosing those connections to journal publishers or the public. Continue to STAT+ to read the full story…

Documentation

STAT+: Journal retracts study tied to Micronoma’s effort to create cancer blood test

STAT

JUNE 26, 2024

“Some of the findings of the article are affected and the corresponding conclusions are no longer supported,” Nature said in the retraction. Nature retracted a high-profile paper that served as part of the scientific groundwork for Micronoma, a San Diego-based startup, on Wednesday.

Opinion: Tackling administrative harm can yield better decisions for better care

STAT

JUNE 25, 2024

O’Donnell in an article in The New England Journal of Medicine. Called administrative harm, it directly influences patient care and outcomes, professional practice, and organizational efficiencies. The term was coined in 2022 by physician Walter J.

Opinion: STAT readers on mask bans, cancer screening, and empathy and AI

STAT

AUGUST 24, 2024

First Opinion is STAT’s platform for interesting, illuminating, and provocative articles about the life sciences writ large, written by biotech insiders, health care workers, researchers, and others.

STAT+: Dana-Farber retracts string of studies in systematic review of data integrity

STAT

APRIL 18, 2024

The issues with this paper, along with concerns with more than 50 other articles co-authored by four of Dana-Farber’s top researchers, were highlighted in a January blog post by the scientific sleuth Sholto David.

Opinion: Readers respond to essays on philanthropy and nursing schools, opioid overdoses, and more

STAT

JULY 20, 2024

First Opinion is STAT’s platform for interesting, illuminating, and maybe even provocative articles about the life sciences writ large, written by biotech insiders, health care workers, researchers, and others.

Drug Pricing

Opinion: First Opinion readers respond to essays on right to try lies, pharma execs, and more

STAT

AUGUST 10, 2024

First Opinion is STAT’s platform for interesting, illuminating, and maybe even provocative articles about the life sciences writ large, written by biotech insiders, health care workers, researchers, and others.

The cardiologist building digital tools to help colleagues stay on top of new research

STAT

OCTOBER 25, 2023

Visit the website of cardiologist Ruey Hu, and you can scroll through his prolific scientific articles neatly arranged into 11 sections by study type, peruse a folder of medical education resources, and browse links to a couple of hand-coded tools. More curiously, there’s also a tab labeled, “Composing.”

Labelling

Opinion: First Opinion readers on cancer screening, mpox vaccines, and more

STAT

SEPTEMBER 7, 2024

First Opinion is STAT’s platform for interesting, illuminating, and provocative articles about the life sciences writ large, written by biotech insiders, health care workers, researchers, and others.

Vaccines

Opinion: Letters on Sonya Massey’s death, vaccine injuries, and much more

STAT

AUGUST 3, 2024

First Opinion is STAT’s platform for interesting, illuminating, and maybe even provocative articles about the life sciences writ large, written by biotech insiders, health care workers, researchers, and others.

Vaccines

Opinion: First Opinion readers on Noah Lyles and Covid-19, the dearth of geriatricians, PBMs, and more

STAT

AUGUST 17, 2024

First Opinion is STAT’s platform for interesting, illuminating, and provocative articles about the life sciences writ large, written by biotech insiders, health care workers, researchers, and others.

Opinion: STAT readers on hospital consolidation, patent system flaws, and asynchronous care

STAT

OCTOBER 26, 2024

First Opinion is STAT’s platform for interesting, illuminating, and provocative articles about the life sciences writ large, written by biotech insiders, health care workers, researchers, and others.

Hospitals

Opinion: Readers respond to a plea for rare disease progress, vaccine-related injury, and more

STAT

JUNE 15, 2024

First Opinion is STAT’s platform for interesting, illuminating, and maybe even provocative articles about the life sciences writ large, written by biotech insiders, health care workers, researchers, and others.

Vaccines

An Ask Me Anything with STAT’s Nicholas St. Fleur

STAT

OCTOBER 28, 2023

Recently, STAT launched a brand-new home for our subscribers to connect with each other and with their favorite STAT journalists. It’s called, appropriately, STAT+ Connect.

STAT+: ‘If this works, it changes everything’: Altos Labs founders lay out plan to reverse disease

STAT

NOVEMBER 15, 2022

For one, the first article about the biotech and its $3 billion stash talked about Silicon Valley billionaires “ living forever.” BOSTON — The executives behind Altos Labs would really, really like people to stop saying they’re trying to reverse aging. They have a couple things going against them on this count.

Handling Drug Patent Invalidity Claims

Drug Patent Watch

DECEMBER 8, 2024

In this article, we will delve into the strategies and considerations for handling drug patent… Source However, with the increasing competition from generic and biosimilar manufacturers, patent invalidity claims have become a significant challenge for pharmaceutical companies.

STAT+: Stump Pharmalot: An Ask Me Anything with Ed Silverman

STAT

FEBRUARY 23, 2024

In 2023, STAT launched a brand-new home for our subscribers to connect with each other and with their favorite STAT journalists.

CDC to cut back on Covid data it collects as public health emergency ends

STAT

MAY 5, 2023

Read the rest…

STAT+: The stories that shaped our understanding of the health care system

STAT

MAY 13, 2024

” The answer invariably comes back to a popular 2003 journal article from a quartet of health economists titled, “ It’s The Prices, Stupid.” ” Continue to STAT+ to read the full story…

Hospitals

Coalition wages campaign for retractions of Richard Lynn’s racist journal articles

Opinion: Journals that published Richard Lynn’s racist ‘research’ articles should retract them

Trending Sources

It’s time to stop treating menopause like a disease, researchers argue in series of Lancet articles

Questions about Pfizer’s GenAI ‘Health Answers’

10 of our most popular articles in 2022

STAT+: U.K. lawmaker wants regulators to probe pharma companies over ‘misleading’ Covid-19 vaccines statements

Journals issue corrections noting vaping researchers’ undisclosed ties to Juul

Pharmaceutical Marketing Articles: Insights, Trends, and Strategies for Pharma Teams

10 of our most read articles in 2023

Article retractions muddy MDMA waters after FDA denial

Top 10 Feature Articles of 2024

STAT+: The U.S. has relied on cheap, effective generic drugs for 40 years. Now that promise is under threat

STAT+: NEJM aims to hold AI to account with new publication

10 of our most read articles of 2024

Heart disease experts in their own words: ‘This is solvable and this is preventable’

Opinion: Readers respond to essays on long Covid, hypochondria, and more

How skeptical should you be of an after-the-fact subgroup analysis in a failed clinical trial?

Mistakes happen in research papers. But corrections often don’t

A STAT analysis shows how top drug companies are starting to take action on climate

Opinion: First Opinion readers on clinical trials in Africa, compounded semaglutide, depressed mice, and more

Opinion: What readers have to say about long Covid, FDA and diversity, and more

Managing Drug Patent Portfolios Effectively

For Eli Lilly’s head scientist, Alzheimer’s results cap a 25-year scientific quest

Opinion: First Opinion readers respond to psychiatry and social contracts, Medicare and weight loss meds, and more

Suicide hotlines promise anonymity. Dozens of their websites send sensitive data to Facebook

STAT+: NYU professors who defended vaping didn’t disclose ties to Juul, documents show

STAT+: Journal retracts study tied to Micronoma’s effort to create cancer blood test

Opinion: Tackling administrative harm can yield better decisions for better care

Opinion: STAT readers on mask bans, cancer screening, and empathy and AI

STAT+: Dana-Farber retracts string of studies in systematic review of data integrity

Opinion: Readers respond to essays on philanthropy and nursing schools, opioid overdoses, and more

Opinion: First Opinion readers respond to essays on right to try lies, pharma execs, and more

The cardiologist building digital tools to help colleagues stay on top of new research

Opinion: First Opinion readers on cancer screening, mpox vaccines, and more

Opinion: Letters on Sonya Massey’s death, vaccine injuries, and much more

Opinion: First Opinion readers on Noah Lyles and Covid-19, the dearth of geriatricians, PBMs, and more

Opinion: STAT readers on hospital consolidation, patent system flaws, and asynchronous care

Opinion: Readers respond to a plea for rare disease progress, vaccine-related injury, and more

An Ask Me Anything with STAT’s Nicholas St. Fleur

STAT+: ‘If this works, it changes everything’: Altos Labs founders lay out plan to reverse disease

Handling Drug Patent Invalidity Claims

STAT+: Stump Pharmalot: An Ask Me Anything with Ed Silverman

CDC to cut back on Covid data it collects as public health emergency ends

STAT+: The stories that shaped our understanding of the health care system

Stay Connected